ERBB2 and breast cancer: The average age of the control group was 37.8±2.4 years and when we evaluated the breast cancer molecular subtypes we noted that the HER-2 group included 10 patients with luminal hybrid tumors (positive for estrogen and/or progesterone and HER-2 receptors) and two patients with HER-2 overexpression.